Nykredit A S Makes New $88.91 Million Investment in Stryker Corporation $SYK

Nykredit A S acquired a new position in shares of Stryker Corporation (NYSE:SYK) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 282,407 shares of the medical technology company’s stock, valued at approximately $88,913,000. Nykredit A S owned about 0.07% of Stryker as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. VanderPol Investments L.L.C. grew its holdings in Stryker by 1.4% in the 4th quarter. VanderPol Investments L.L.C. now owns 2,084 shares of the medical technology company’s stock valued at $732,000 after buying an additional 28 shares during the period. KCM Investment Advisors LLC lifted its holdings in shares of Stryker by 1.5% during the 4th quarter. KCM Investment Advisors LLC now owns 1,857 shares of the medical technology company’s stock worth $653,000 after acquiring an additional 28 shares during the period. Rossby Financial LCC lifted its holdings in shares of Stryker by 6.6% during the 4th quarter. Rossby Financial LCC now owns 451 shares of the medical technology company’s stock worth $159,000 after acquiring an additional 28 shares during the period. Tcfg Wealth Management LLC boosted its position in shares of Stryker by 2.7% in the third quarter. Tcfg Wealth Management LLC now owns 1,091 shares of the medical technology company’s stock worth $403,000 after acquiring an additional 29 shares during the last quarter. Finally, ICW Investment Advisors LLC grew its holdings in Stryker by 0.6% in the fourth quarter. ICW Investment Advisors LLC now owns 5,096 shares of the medical technology company’s stock valued at $1,791,000 after purchasing an additional 30 shares during the period. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the stock. BMO Capital Markets initiated coverage on shares of Stryker in a research note on Wednesday, July 8th. They set an “outperform” rating and a $369.00 price target on the stock. BTIG Research lowered their price objective on shares of Stryker from $371.00 to $358.00 and set a “buy” rating for the company in a research note on Friday, July 31st. Wall Street Zen raised Stryker from a “hold” rating to a “buy” rating in a research report on Saturday, August 8th. Leerink Partners reduced their target price on Stryker from $410.00 to $407.00 and set an “outperform” rating on the stock in a report on Friday, June 5th. Finally, Truist Financial boosted their price target on Stryker from $330.00 to $340.00 and gave the company a “hold” rating in a research report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $386.28.

Key Stories Impacting Stryker

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Director Mary Brainerd purchased additional Stryker shares on September 2, increasing her personal stake. Insider buying can signal confidence in the company’s valuation and outlook, although the purchase alone is unlikely to materially change earnings expectations. Stryker Insider Makes Bold New Move With Fresh Share Purchase
• Positive Sentiment: Stryker received FDA De Novo authorization for SportSuite Vision, its surgical application for Apple Vision Pro, and completed the first reported hip arthroscopy using the system. The technology could strengthen Stryker’s digital-surgery and orthopedic innovation offerings, though commercial adoption remains to be demonstrated. Stryker introduces FDA-authorized surgical application for Apple Vision Pro
• Positive Sentiment: Stryker agreed to acquire ZuriMED, adding the FiberLocker System and expanding its shoulder-care and rotator-cuff portfolio. The deal could broaden Stryker’s orthopedic product lineup and growth opportunities. Stryker to Acquire ZuriMED to Expand Its Shoulder Care Portfolio
• Neutral Sentiment: Analysts remain broadly optimistic about Stryker’s longer-term prospects even as the shares have underperformed the broader market. The company’s latest reported quarter exceeded earnings expectations, but its valuation remains relatively elevated, which can increase sensitivity to growth concerns. Is Stryker Stock Underperforming the Nasdaq?
• Negative Sentiment: The recent underperformance suggests investors may be focused more on valuation, execution, and market-wide factors than on the new product announcements. The ZuriMED transaction also introduces integration and spending risks, with financial terms and its near-term earnings contribution not specified in the available reports.

Insiders Place Their Bets

In other Stryker news, insider Dylan Bram Crotty sold 441 shares of the business’s stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $328.61, for a total transaction of $144,917.01. Following the transaction, the insider owned 6,102 shares in the company, valued at $2,005,178.22. The trade was a 6.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Ronda E. Stryker sold 300,000 shares of the company’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $335.90, for a total value of $100,770,000.00. Following the completion of the sale, the director directly owned 2,301,375 shares of the company’s stock, valued at $773,031,862.50. The trade was a 11.53% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 351,267 shares of company stock worth $118,197,701 over the last quarter. 4.60% of the stock is owned by corporate insiders.

Stryker Price Performance

SYK opened at $312.10 on Thursday. Stryker Corporation has a 52-week low of $281.00 and a 52-week high of $396.86. The company has a 50 day moving average of $329.60 and a two-hundred day moving average of $330.33. The company has a market cap of $119.71 billion, a P/E ratio of 32.34, a P/E/G ratio of 1.99 and a beta of 0.76. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK) last issued its earnings results on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, beating analysts’ consensus estimates of $3.49 by $0.20. The business had revenue of $6.59 billion for the quarter, compared to the consensus estimate of $6.58 billion. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The business’s revenue for the quarter was up 9.4% compared to the same quarter last year. During the same quarter last year, the firm posted $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, analysts expect that Stryker Corporation will post 15.02 earnings per share for the current year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be given a $0.88 dividend. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 annualized dividend and a yield of 1.1%. Stryker’s dividend payout ratio (DPR) is 36.48%.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.